|
|
|
Article Cited by others ORIGINAL ARTICLE
A meta-analysis of bevacizumab combined with chemotherapy in the treatment of ovarian cancer
Wang T S, Lei W, Cui W, Wen P, Guo H F, Ding S G, Yang Y P, Xu Y Q, Lv S W, Zhu Y L
Year : 2014| Volume: 51| Issue : 7 | Page no: 95-98 | This article has been cited by | | 1 |
Risk of Thrombo-Embolic Events in Ovarian Cancer: Does Bevacizumab Tilt the Scale? A Systematic Review and Meta-Analysis |
|
| | Michael Saerens, Emiel A. De Jaeghere, Heini Kanervo, Nele Vandemaele, Hannelore Denys, Eline Naert | | | Cancers. 2021; 13(18): 4603 | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer |
|
| | Liina Salminen, Nimrah Nadeem, Shruti Jain, Seija Grènman, Olli Carpén, Sakari Hietanen, Sinikka Oksa, Urpo Lamminmäki, Kim Pettersson, Kamlesh Gidwani, Kaisa Huhtinen, Johanna Hynninen | | | Gynecologic Oncology. 2020; 156(3): 689 | | | [Pubmed] [Google Scholar] [DOI] | | | 3 |
Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic Reviews |
|
| | Marina T Van Leeuwen, Steven Luu, Howard Gurney, Martin R Brown, Sallie-Anne Pearson, Kate Webber, Lee Hunt, Soojung Hong, Geoffrey P Delaney, Claire M Vajdic | | | JNCI Cancer Spectrum. 2020; 4(6) | | | [Pubmed] [Google Scholar] [DOI] | | | 4 |
Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer |
|
| | Chi-Kang Lin, Meng-Yi Bai, Teh-Min Hu, Yu-Chi Wang, Tai-Kuang Chao, Shao-Ju Weng, Rui-Lan Huang, Po-Hsuan Su, Hung-Cheng Lai | | | Oncotarget. 2016; 7(8): 8993 | | | [Pubmed] [Google Scholar] [DOI] | |
|
|
